HHS cancels $500M BARDA mRNA contracts

Summary

On August 5-6, 2025, HHS announced the termination of 22 BARDA-funded mRNA vaccine contracts valued at approximately $500 million, including projects with Moderna and Pfizer. A separate $766 million Moderna pandemic influenza mRNA contract was cancelled May 28, 2025. Former BARDA director Rick Bright called the decision a "self-inflicted vulnerability."

What happened

HHS stated BARDA was terminating the contracts because mRNA vaccines "fail to protect effectively against upper respiratory infections like COVID and flu" - a claim scientists and health experts broadly rejected as factually incorrect. The 22 cancelled contracts were in development phases; clinical evidence on mRNA vaccines supports their effectiveness against severe disease and hospitalization. The Moderna H5N1 mRNA vaccine ($766 million, cancelled May 28, 2025) had just reported positive interim results from a Phase I trial in 300 healthy adults when the contract was withdrawn. Rick Bright (former BARDA director) stated: "By dismantling that platform, we're crippling our front-line defense." Vaccine expert Paul Offit called it "a giant step backward for science."

Impact on the United States

Loss of US mRNA platform capacity for rapid pandemic response; elimination of H5N1 bird-flu vaccine development at a time when H5N1 remains an active pandemic threat; reduced ability to mount a rapid vaccine response to the next novel respiratory virus.

Global ripple effects

Reduced US pandemic readiness increases vulnerability to future global outbreaks, including H5N1, that could return to harm US health security.

Documented effects

1. Aug 202522 mRNA contracts (~$500M) terminated August 5-6, 2025; includes Moderna and Pfizer projects[1]
2. May 2025$766M Moderna H5N1 mRNA vaccine contract cancelled May 28, 2025, as Moderna announced positive interim early-stage trial results[2]
3. Former BARDA director Rick Bright called the decision a "self-inflicted vulnerability"[3]

Why this is rated significant

Canceling $500M in mRNA contracts undercuts pandemic-preparedness capacity, a significant national-security vulnerability that is prospective rather than realized.

Corrections & updates [5]

Every change to a fact on this page after publication is logged here, newest first.

1. Sep 29, 2026CorrectedQuote

   The entry said former BARDA directors called the terminations a 'national security vulnerability.' Neither cited source contains that phrase. STAT reports that Rick Bright, a former BARDA director, called the decision a 'self-inflicted vulnerability.' The attribution and quote are corrected.[3]

2. Sep 29, 2026CorrectedKey facts

   CNBC reports the $766 million Moderna contract was cancelled as Moderna announced positive interim early-stage trial results, not 'days after' them.[2]

   Previously

   $766M Moderna H5N1 mRNA vaccine contract cancelled May 28, 2025, days after positive Phase I results

   Now

   $766M Moderna H5N1 mRNA vaccine contract cancelled May 28, 2025, as Moderna announced positive interim early-stage trial results

3. Sep 29, 2026CorrectedSummary card

   The summary card said 'dozens' of contracts were cancelled and that 'former BARDA directors' warned about the decision. HHS terminated 22 contracts, and the warning quoted is from one former BARDA director, Rick Bright.[1][2][3]

   + Show previous and current text- Hide previous and current text

   Previously

   HHS cancelled dozens of BARDA-funded mRNA development contracts, including a Moderna H5N1 pandemic-influenza vaccine with positive early results. Former BARDA directors warned the decision cripples US capacity to develop rapid vaccine responses.

   Now

   HHS cancelled 22 BARDA-funded mRNA vaccine contracts worth about $500 million, after separately cancelling a $766 million Moderna H5N1 pandemic-influenza vaccine contract. Former BARDA director Rick Bright called the decision a "self-inflicted vulnerability."

4. Sep 29, 2026ClarifiedSource labels

   Source tier labels brought in line with the site's tier rule (specialist and trade publications are Tier 3; general news organizations are Tier 2): BioPharma Dive (Tier 2 to 3); STAT (Tier 2 to 3). No claim in the entry changed.

5. Sep 29, 2026CorrectedCost estimate

   The block booked the full $1.266B in cancelled awards as a federal saving. But $766M was the total awarded to Moderna, not the unpaid balance, and HHS said it would redirect the other ~$500M to different vaccine platforms. The sunk-cost and broader figures had no source. Nothing is booked until the actual unpaid and already-spent amounts are published.

   Previously

   net -$916M so far (gross $350M, saved $1.266B); 10yr -$916M; 15yr -$916M; broader $2B

   Now

   net $0; 10yr $0; 15yr $0; broader $0

Sources [3]